Get the Daily Brief
Latest Biotech News
Neuro M&A: UCB buys Neurona Therapeutics
UCB moved deeper into epilepsy with its latest acquisition, paying up to $1.15 billion for Neurona Therapeutics. The deal includes a $650 million upfront payment and additional milestone tranches,...
Cardiovascular AI screening tool for aortic stenosis
A new smart-finger cuff algorithm reported high accuracy for detecting moderate-to-severe aortic stenosis in an at-risk subgroup of African American patients. The REACH trial results were...
Retinal gene therapy financing for late-stage progression
Ray Therapeutics raised a $125 million Series B to advance its retinal gene therapy program RTx-015 for retinitis pigmentosa. The financing is intended to fund late-stage clinical development and...
Biotech venture funding: seed round for inflammation-associated anemia
Ferrosa Therapeutics secured $3.5 million in seed funding for FRS-101, a first-in-class bispecific antibody program intended for anemia of inflammation. The company is targeting multiple areas...
Synthetic control arms reframe clinical trial design
A new innovation spotlight highlighted synthetic control arms as an alternative to traditional placebo-heavy trial designs, using external datasets to estimate counterfactual outcomes. The...
C-suite expansion ahead of lanifibranor Phase III readout
Inventiva reshuffled its leadership team as it prepares for a Phase III readout for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) targeted for 4Q26. The company named a...
Tempus and USC expand precision medicine alliance
Tempus AI signed an agreement with the University of Southern California to deploy molecular diagnostics and comprehensive genomic profiling for clinical precision medicine use across USC’s Keck...
Seed science: glioma CAR-neutrophils developed
Researchers reported progress toward in vivo CAR-neutrophil engineering as a potential new modality for glioma treatment. The approach centers on direct genetic programming of neutrophils—an area...
EU greenlights Sanofi tolebrutinib for secondary progressive MS after FDA rejection
The European Medicines Agency’s CHMP has recommended approval of Sanofi’s BTK inhibitor Cenrifki (tolebrutinib) for a targeted subgroup of patients with non-relapsing secondary progressive...
FDA priority vouchers accelerate psychedelic drug review for depression and PTSD
The FDA has issued priority review vouchers tied to three psychedelic programs, as part of the Trump administration’s push to expand access to mental health treatments. The agency’s announcement...
Regulatory setback in aneurysmal subarachnoid hemorrhage NDA as FDA issues CRL
Grace Therapeutics said the FDA has issued a complete response letter for its GTx-104 NDA, delaying its effort to update the standard of care in aneurysmal subarachnoid hemorrhage. Grace...
Lilly-CureVac-era funding and venture momentum as Kurma closes €215M fund
Kurma Partners has closed its fourth and largest fund, raising €215 million to pursue disruptive therapeutic solutions. The firm’s new vehicle signals continued investor appetite for early- to...
Ray Therapeutics raises $125M Series B to advance optogenetic retinal gene therapy
Ray Therapeutics raised $125 million in a Series B financing to advance its retinal gene therapy platform, including late-stage development and commercial readiness for its lead program RTx-015 in...
Protein engineering and immuno-oncology targeting: cFLIP vulnerability in aggressive DLBCL
Researchers at the University of Cologne’s Center for Molecular Medicine Cologne (CMMC) identified a potential vulnerability in diffuse large B-cell lymphoma (DLBCL), highlighting cFLIP as a...
Cell therapy manufacturing: bioreactor method produces 40M macrophages per week
Hannover Medical School (MHH) reported a scalable method to turn induced pluripotent stem cells into immune-cell factories using medium-sized bioreactors. In Nature Protocols, the team described...
Single-cell cancer risk engineering: microfluidic mechano-NPS predicts breast cancer susceptibility
City of Hope and UC Berkeley researchers reported a microfluidic platform that uses physical stress as a cellular readout of breast cancer risk. In eBioMedicine, the team described...
Advanced imaging expands BBB-capable autophagy enhancer discovery with AI screening
DeepDrugDiscovery unveiled an AI-driven screening platform aimed at finding autophagy enhancers that can penetrate the blood–brain barrier and address Alzheimer’s disease pathology. The approach...
Neural network control improves high-speed nano-positioning precision
Huazhong University of Science and Technology and the University of Victoria reported a neural-network-based switching controller designed to improve precision and responsiveness in high-speed...
EU regulatory approval for Sanofi MS drug after FDA rejection
Sanofi’s tolebrutinib, marketed as Cenrifki for secondary progressive multiple sclerosis, received a positive European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)...
FDA approval of first gene therapy for hearing loss under national priority vouchers
Regeneron won an FDA approval for Otarmeni, a gene therapy targeting a rare inherited form of hearing loss. The approval is notable as the first gene therapy cleared under the agency’s national...